Cytosorbents Corporation CTSO
$5.75
$0.020.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 8.68% | -4.01% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.68% | -4.01% | |||
| Cost of Revenue | -5.49% | 12.51% | |||
| Gross Profit | 14.99% | -9.91% | |||
| SG&A Expenses | -2.27% | -15.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.78% | -10.37% | |||
| Operating Income | 22.21% | 24.86% | |||
| Income Before Tax | 13.88% | 6.69% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.88% | 6.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.88% | 6.69% | |||
| EBIT | 22.21% | 24.86% | |||
| EBITDA | 25.06% | 27.03% | |||
| EPS Basic | 14.06% | 6.51% | |||
| Normalized Basic EPS | 19.18% | -11.57% | |||
| EPS Diluted | 14.06% | 6.51% | |||
| Normalized Diluted EPS | 19.18% | -11.57% | |||
| Average Basic Shares Outstanding | 0.11% | -0.10% | |||
| Average Diluted Shares Outstanding | 0.11% | -0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||